可溶性P-选择素和CD40L与2型糖尿病合并冠心病的相关性被引量：2

导出

摘要目的探讨可溶性P选择素(sP-Selectin)和CD40L与2型糖尿病(T2DM)合并冠心病之间的关系。方法将87例T2DM患者分为40例T2DM合并冠心病(T2DM+CHD)组和47例单纯T2DM组,选择同期正常健康人32例(年龄、性别与T2DM组相匹配)作为正常对照组,采用双抗夹心酶联免疫吸附检测sP-Selectin和CD40的水平,并作相关分析。结果 T2DM组的P-Selectin、CD40L显著高于正常对照组(P<0.05)。T2DM+CHD组sP-Selectin、CD40L高于T2DM组(P<0.05),T2DM+CHD组的CD40L与体重指数(BMI)、收缩压(SBP)、甘油三酯(TG)、空腹血糖(FPG)、低密度脂蛋白(LDL)、sP-Selectin正相关(r=0.53,0.52,0.66,0.58,0.46,0.618,P<0.05),与HDL呈负相关(相关系数r=-0.40,P<0.05)。结论 sP-Selectin、CD40L与T2DM并冠心病之间存在密切的相关性,在T2DM并冠心病的发生、发展中起着重要作用,测定sP-Selectin、CD40L可能作为T2DM并冠心病的预测因子。

作者冯涛李华田勇翟倩倩商丽娜

机构地区郑州大学第一附属医院老年内分泌科郑州市人民医院

出处《中国老年学杂志》 CAS CSCD 北大核心 2013年第14期3298-3300,共3页 Chinese Journal of Gerontology

关键词可溶性P-选择素可溶性CD40L 2型糖尿病冠心病

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献8

1Hu H, Hjemdahl P,Li N ,et al. Effects of insulin on platelet a leu-kocyteactivity in whole blood[ J]. Thromb Res,2002 ;1 (5 ) :209-15.
2Devaraj S,Chan Ar Jr,Jialal I. Alpha-Tocopherol supplementation decrea-ses plasminogen activator inhibitor-1 and P-selectin levels in type 2 dia-betic patients[ J]. Diabetes Care,2002;25(3) :524-9.
3Ferroni P,Basili S,Falco A,et al. Platelet activation in type 2 diabetesmellitus[ J]. J Thromb Haemost,2004;2(8) : 1282-91.
4Grant PJ.Diabetes mellitus as a prothrombotic condition [ J ] . J InternMed,2007,-262(2) :157-72.
5Phipps RP. Atherosclerosis: the emerging role of inflammation and theCD40-CD40 ligand system(J]. Proc Natl Acad Sci USA,2000;97( 13):6930-2.
6SchonbeckU,Libby P. CD40 signaling and plaque instability[ J]. CircRes,2001;89(12) : 1092-103.
7张峻,陈纪林,顾晴,关婷,陈曦.阻断CD40-CD40配体系统对动脉粥样硬化的影响[J].中国动脉硬化杂志,2006,14(2):119-122. 被引量：18
8曹鸿霖,涂传清.CD 40/CD 40L与血栓性疾病研究进展[J].血栓与止血学,2008,14(4):188-190. 被引量：8

二级参考文献25

1缪宇锋,张润玲,李光迪.急性脑缺血及脑梗死患者外周血单核细胞CD40L的表达与变化对病情及预后的评估作用[J].中国临床康复,2005,9(5):106-107. 被引量：6
2徐邦牢,王蓉,贝春花,雷秀霞.1型糖尿病患者血清sCD40L测定的临床意义[J].中国热带医学,2005,5(7):1432-1433. 被引量：2
3Libby P, Rkdker PM, Maseri A. Inflammation and atherosclerosis[J]. Circulation, 2002, 105 (9): 1 135-143
4Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease[J]. Circulation, 2002, 106 (8): 896-899
5Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype[J]. Proc Natl Acad Sci, 2000, 97 (13): 7 464-469
6Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40signaling limits evolution of established atherosclerosis in mice[J]. Proc Natl Acad Sci, 2000, 97 (13): 7 458-463
7Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes[J]. N Engl J Med, 2003, 348 (12): 1 104-111
8Buremmer D, Riggers U, Holzmeister J, Grill M, Lippek F, Settmacher U, et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions[J]. Am J Cardiol, 2001, 87 (1): 21-27
9金冬雁, 黎孟枫. 分子克隆试验指南[M]. 第二版, 科学出版社, 1998
10Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, et al. Elevation of plasma high density lipoprotein concentration reduces interleukin-12 induced expression of E-selectiin in an In Vivo model of acute inflammation[J]. Circulation, 2001, 103 (2): 108-112